Sinovac’s Vaccine Trial Data Suggest Potential in Virus Defense

Vaccine found to be safe and capable of inducing antibodies
Sinovac will conduct phase III trial on humans in Brazil

An engineer shows an experimental vaccine for the COVID-19 coronavirus that was tested at the Quality Control Laboratory at the Sinovac Biotech facilities in Beijing.Photographer: Nicolas Asfouri/AFP via Getty Images

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Bloomberg News

June 14, 2020 at 1:49 AM UTC

This article is for subscribers only.

We're tracking the latest on the coronavirus outbreak and the global response. Sign up here for our daily newsletter on what you need to know.

Sinovac Biotech Ltd. said its coronavirus shot is safe and capable of eliciting an immune response from human trials, suggesting the shot’s potential in defending against infection of the novel coronavirus.